Latest Breaking News On - Beijing boren hospital - Page 1 : comparemela.com

email article Donor-derived anti-CD7 chimeric antigen receptor (CAR) T-cell therapy led to complete responses in 18 of 20 patients with relapsed or refractory (r/r) T-cell acute lymphoblastic leukemia (ALL), a first-in-human clinical trial showed. After a median follow-up of 6.3 months, 15 of the 18 responding patients remained in remission, and seven patients had undergone stem-cell transplantation (SCT). All patients developed cytokine release syndrome (CRS), which was grade 1/2 in most instances. Because the therapy involved unmanipulated T cells, a majority of patients developed graft-versus-host disease (GVHD), grade 1/2 severity in all cases. All of the patients developed severe cytopenias, which were manageable. The results provided the basis for an ongoing phase II trial of the donor-derived anti-CD7 therapy, reported Jing Pan, MD, of the State Key Laboratory of Experimental Hematology and Beijing Boren Hospital in China, and colleagues in the

Jing panCharles bankheadJohn dipersioKey laboratory of experimental hematologyWashington university in stState key laboratoryExperimental hematologyBeijing boren hospitalWashington universityMedpage todayஜிங் பான்சார்லஸ் வங்கித் தலைவிசை ஆய்வகம் ஆஃப் சோதனை ஹீமாட்டாலஜிவாஷிங்டன் பல்கலைக்கழகம் இல் ஸ்டம்ப்நிலை விசை ஆய்வகம்சோதனை ஹீமாட்டாலஜி